Hans Peter Horny

Summary

Country: Germany

Publications

  1. ncbi Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings
    H P Horny
    Institute of Pathology, Medical University of Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    Leuk Res 25:543-51. 2001
  2. ncbi Histopathological and immunohistochemical aspects of mastocytosis
    Hans Peter Horny
    Institute of Pathology, Medical University of Lubeck, Germany
    Int Arch Allergy Immunol 127:115-7. 2002
  3. pmc Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge
    H P Horny
    Institute of Pathology, University of Lubeck, D 23538 Lubeck, Germany
    J Clin Pathol 57:604-8. 2004
  4. pmc Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens
    H P Horny
    Institute of Pathology, University of Lubeck, D 23538 Lubeck, Germany
    J Clin Pathol 56:575-8. 2003
  5. pmc Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study
    H P Horny
    Institute of Pathology, University of Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    J Clin Pathol 56:103-6. 2003
  6. pmc The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers
    H P Horny
    University of Lubeck, Institute of Pathology, Lubeck, Germany
    J Clin Pathol 59:298-302. 2006
  7. pmc An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL)
    H P Horny
    Institute of Pathology, University of Lubeck, Germany
    J Clin Pathol 59:264-8. 2006
  8. ncbi [Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]
    Hans Peter Horny
    Institut fur Pathologie, Medizinische Universität zu Lübeck MUL, Lubeck
    Wien Klin Wochenschr 114:222-8. 2002
  9. ncbi Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia
    Manuela Krokowski
    Institute of Pathology, University of Lubeck, Lubeck, Germany
    Am J Clin Pathol 124:560-8. 2005
  10. ncbi Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia
    Karl Sotlar
    Institute of Pathology, University of Tubingen, Liebermeisterstrasse 8, D 72076, Tubingen, Germany
    Leuk Res 26:979-84. 2002

Collaborators

Detail Information

Publications52

  1. ncbi Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings
    H P Horny
    Institute of Pathology, Medical University of Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    Leuk Res 25:543-51. 2001
    ....
  2. ncbi Histopathological and immunohistochemical aspects of mastocytosis
    Hans Peter Horny
    Institute of Pathology, Medical University of Lubeck, Germany
    Int Arch Allergy Immunol 127:115-7. 2002
    ..The demonstration of expression of vascular endothelial growth factor by mast cells is consistent with the finding of angiogenesis which is commonly seen in tissue infiltrates of mastocytosis...
  3. pmc Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge
    H P Horny
    Institute of Pathology, University of Lubeck, D 23538 Lubeck, Germany
    J Clin Pathol 57:604-8. 2004
    ....
  4. pmc Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens
    H P Horny
    Institute of Pathology, University of Lubeck, D 23538 Lubeck, Germany
    J Clin Pathol 56:575-8. 2003
    ....
  5. pmc Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study
    H P Horny
    Institute of Pathology, University of Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    J Clin Pathol 56:103-6. 2003
    ..Tryptase is constitutively expressed by all MC, whereas chymase is found only in an MC subset. Very little is known about chymase expression in MC proliferative disorders (mastocytosis)...
  6. pmc The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers
    H P Horny
    University of Lubeck, Institute of Pathology, Lubeck, Germany
    J Clin Pathol 59:298-302. 2006
    ....
  7. pmc An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL)
    H P Horny
    Institute of Pathology, University of Lubeck, Germany
    J Clin Pathol 59:264-8. 2006
    ..This report contributes to the differential diagnosis of ISM by demonstrating that such lymphocytic aggregates may be neoplastic...
  8. ncbi [Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]
    Hans Peter Horny
    Institut fur Pathologie, Medizinische Universität zu Lübeck MUL, Lubeck
    Wien Klin Wochenschr 114:222-8. 2002
    ....
  9. ncbi Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia
    Manuela Krokowski
    Institute of Pathology, University of Lubeck, Lubeck, Germany
    Am J Clin Pathol 124:560-8. 2005
    ..Our data show that the infiltration pattern in SM correlates with the disease subtype and should be recognized as an important aspect in the histomorphologic evaluation of the bone marrow...
  10. ncbi Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia
    Karl Sotlar
    Institute of Pathology, University of Tubingen, Liebermeisterstrasse 8, D 72076, Tubingen, Germany
    Leuk Res 26:979-84. 2002
    ....
  11. ncbi CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens
    Karl Sotlar
    Institute of Pathology, University of Tubingen, Tubingen, Germany
    Am J Surg Pathol 28:1319-25. 2004
    ..CD25 therefore appears to be a reliable immunohistochemical marker for the discrimination of neoplastic from normal/reactive MCs, with potential as a diagnostic tool in SM...
  12. ncbi Mastocytosis: state of the art
    Hans Peter Horny
    Institute of Pathology, Ansbach, Germany
    Pathobiology 74:121-32. 2007
    ....
  13. doi Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)
    Karl Sotlar
    Institute of Pathology, University of Munich, Germany
    J Pathol 220:586-95. 2010
    ....
  14. pmc Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD8
    Karl Sotlar
    Institute of Pathology, University of Tubingen, Liebermeisterstrasse 8, D 72076 Tubingen, Germany
    J Mol Diagn 10:58-66. 2008
    ..Altogether, these data suggest that KIT(D816V+) SM can co-exist with JAK2(V617F+) CIMF and that, in some of these SM-CIMF cases, the two mutations are present in the neoplastic cells of both disease components...
  15. doi Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis
    Karl Sotlar
    Institute of Pathology, University of Munich, Munich, Germany
    Mod Pathol 24:585-95. 2011
    ..Upregulated expression of CD30 in advanced systemic mastocytosis may thus be employed as a potential marker for grading systemic mastocytosis in hematopathology...
  16. pmc One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes
    Karl Sotlar
    Institute of Pathology, University of Tubingen, Tubingen, Germany
    Am J Pathol 162:737-46. 2003
    ....
  17. ncbi Bone marrow mastocytosis associated with IgM kappa plasma cell myeloma
    Florian Stellmacher
    Institute of Pathology, University of Lubeck, Ratzeburger Allee 160, D 23538, Lubeck, Germany
    Leuk Lymphoma 45:801-5. 2004
    ....
  18. ncbi Primary diagnosis of Whipple's disease in bone marrow
    Stefan Martin Krober
    Institute of Pathology, University of Tubingen, Tubingen, Germany
    Hum Pathol 35:522-5. 2004
    ....
  19. ncbi Application of novel tissue microarrays to investigate expression of tryptase, chymase and KIT protein in placental mast cells
    Frank Noack
    Department of Pathology, University Hospital Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Arch Gynecol Obstet 272:223-8. 2005
    ..Because little is known about the role of mast cells in the placenta, we investigated the number and expression of chymase, tryptase, and KIT protein in placental mast cells using newly developed tissue microarrays...
  20. ncbi Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes
    Hans Peter Horny
    Institute of Pathology, D 91522 Ansbach, Germany
    Leuk Res 31:1609-16. 2007
    ..Histologic/immunohistochemical investigation of the bone marrow therefore is strongly recommended for patients with (suspected) MDS, the minimum marker-panel suggested being CD31, CD34, and tryptase...
  21. doi Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis
    Sabina Berezowska
    Institute of Pathology, University of Munich, Munich, Germany
    Mod Pathol 27:19-29. 2014
    ..This study demonstrates, for the first time, that almost all patients with adult-onset mastocytosis in the skin, in fact, have systemic mastocytosis with cutaneous involvement...
  22. ncbi Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma
    Stefan Kruger
    Institute of Pathology, University of Schleswig Holstein, Campus Lubeck, Lubeck, Germany
    Oncology 68:269-75. 2005
    ..Our aim was to analyze KIT expression immunohistochemically in renal cell carcinomas (RCCs) and in oncocytomas...
  23. ncbi Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V
    Frank Noack
    Department of Pathology, University of Luebeck, Luebeck, Germany
    Leuk Lymphoma 45:2295-302. 2004
    ..However, additional (but yet unknown) molecular (genetic) defects have to be considered to explain the extremely heterogenous clinical course in these patients...
  24. ncbi Adult hypocellular acute leukaemia with lymphoid differentiation
    Stefan Martin Krober
    Institute of Pathology, University of Tubingen, D 72076, Tubingen, Germany
    Leuk Lymphoma 44:1797-801. 2003
    ..The clinical course appears to be similar to that of hypocellular AML, as neither patient has developed overt leukemia during the one-year follow-up period...
  25. ncbi Primary extranodal NK/T cell lymphoma ("nasal type") of the endometrium: report of an unusual case diagnosed at autopsy
    Juliane Briese
    Department of Gynaecopathology, Institute of Pathology, University Clinic, Martinistrasse 52, DE 20246 Hamburg, Germany
    Gynecol Obstet Invest 61:164-6. 2006
    ..Primary natural killer (NK)/T cell lymphoma of the female genital tract is extremely rare. We here report the case of a "nasal type" NK/T cell lymphoma arising in the uterus. The diagnosis was established only at autopsy...
  26. ncbi Lethal outcome in xanthogranulomatous endometritis
    Frank Noack
    Department of Pathology, University Clinic Schleswig Holstein, Campus Lubeck, Lubeck, Germany
    APMIS 114:386-8. 2006
    ..Because this condition may mimic malignant disease macroscopically and histologically, knowledge of XE is of major importance for both pathologists and gynecologists...
  27. ncbi Review
    Hans Peter Horny
    University of Lubeck, Lubeck, Germany
    Clin Adv Hematol Oncol 2:752. 2004
  28. ncbi Myocardial infarction as an uncommon clinical manifestation of intravascular large cell lymphoma
    Alexander Bauer
    Dept of Internal Medicine I, University of Lubeck, Germany
    Acta Cardiol 60:551-5. 2005
    ..To the best of the authors' knowledge myocardial infarction as a leading symptom of IVL has not been described...
  29. doi Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells
    Hans Peter Horny
    Institute of Pathology, D 91522 Ansbach, Germany
    Am J Clin Pathol 132:438-47. 2009
    ..Expression of CD25 on mast cells is defined as a minor diagnostic criterion and is usually seen only in mastocytosis but not in reactive states of mast cell hyperplasia...
  30. ncbi Splenic mastocytosis: report of two cases and detection of the transforming somatic C-KIT mutation D816V
    Friedrich Wimazal
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    Leuk Lymphoma 45:723-9. 2004
    ..In summary, our data show that the spleen can be a primary site of disease in rare cases of SM. Mastocytosis should therefore be considered as a (rare) differential diagnosis in patients with splenomegaly of unknown etiology...
  31. ncbi Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease
    Wolfgang R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Int Arch Allergy Immunol 128:136-41. 2002
    ..The serum tryptase level is used as a diagnostic marker in mastocytosis and is considered to reflect the burden of (neoplastic) mast cells (MC)...
  32. ncbi Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    J Allergy Clin Immunol 114:3-11; quiz 12. 2004
    ..The current review provides an overview of mastocytosis and its subvariants and a practical guide that might help to delineate mastocytosis from unrelated systemic disorders...
  33. ncbi Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis
    Maria Theresa Krauth
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
    Hum Pathol 37:439-47. 2006
    ..Histidine decarboxylase should therefore be considered as a new MC marker in the screen panel of antigens used to diagnose high-grade MC malignancies...
  34. ncbi Mast cell proliferative disorders: current view on variants recognized by the World Health Organization
    Peter Valent
    Department of Internal Medicine 1, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    Hematol Oncol Clin North Am 17:1227-41. 2003
    ..In patients with SM-AHNMD, the SM should be treated as if no AHNMD is present, and the AHNMD should be treated as if no SM had been diagnosed...
  35. ncbi Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria
    John Hendrik Jordan
    Department of Internal Medicine 1, University of Vienna, Wahringer Gurtel, Austria
    Leuk Lymphoma 43:575-82. 2002
    ..Based on our case and similar cases mimicking mastocytosis, it seems of importance to apply recently established SM criteria in order to discriminate between reactive MC hyperplasia and true mastocytosis with certainty...
  36. ncbi Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Hematol J 3:90-4. 2002
    ..In the few patients recorded so far, a complex karyotype without recurring anomaly was found. The prognosis appears to be grave, although complete remission in response to chemotherapy has been described...
  37. ncbi Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis
    Wolfgang R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Int Arch Allergy Immunol 127:140-2. 2002
    ..No general guidelines for the treatment of patients with SM-AHNMD have been established so far. A reasonable straightforward approach may be to treat the AHNMD in those patients in the same way as if no coexisting SM exists...
  38. ncbi Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma
    Andreas Chott
    Department of Pathology, University of Vienna, Vienna, Austria
    Am J Surg Pathol 27:1013-9. 2003
    ..Together, neoplastic mast cells in a case of mast cell sarcoma were found to exhibit unique morphologic, phenotypical, and molecular features when compared with mast cells in indolent mastocytosis or normal tissue mast cells...
  39. ncbi Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis
    Martin Anlauf
    Department of Pathology, University of Kiel, Michaelisstr 11, 24105 Kiel, Germany
    J Histochem Cytochem 54:201-13. 2006
    ....
  40. ncbi Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders
    Hermine Agis
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Am J Clin Pathol 125:273-81. 2006
    ..In summary, BB1 (basogranulin) is a new immunohistochemical basophil marker that should allow quantification of basophils in CML at diagnosis and during therapy...
  41. ncbi Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category
    Minoo Ghannadan
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    Am J Clin Pathol 119:663-71. 2003
    ..In summary, VEGF expression in the bone marrow is restricted to certain stages of differentiation and maturation of myeloid cells and correlates with the FAB category...
  42. ncbi Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis
    Hermine Agis
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Leuk Res 29:1227-32. 2005
    ..The exact knowledge of the pathology and target-profile of the associated leukemias in SM have important therapeutic implications...
  43. ncbi Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes
    Stefan Florian
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int Arch Allergy Immunol 136:273-80. 2005
    ..In those who lack skin lesions, mastocytosis is often overlooked or confused with endocrinologic, allergic, or other internal disorders...
  44. ncbi Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression
    Peter Valent
    Department of Internal Medicine I, Division of Hematology, University of Vienna, Austria
    Int Arch Allergy Immunol 127:137-9. 2002
    ..In the present article, we discuss clinical and laboratory findings in smouldering SM and review the current literature. In addition, the pathophysiology of this novel subtype of SM is discussed...
  45. ncbi Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia
    Olaf Penack
    Ann Hematol 84:692-3. 2005
  46. doi Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Lymphoma 49:635-8. 2008
    ..Application of these markers may assist in determining the phase of disease and may help to better predict the prognosis in individual patients...
  47. ncbi Sustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipient
    Markus G Manz
    Department of Medicine II, Eberhard Karls University, Tubingen, Germany
    Transplantation 73:995-7. 2002
    ..We report a case of EBV-PTL resolving rapidly after alleviation of immunosuppression. A strong cytotoxic memory T cell (CTL) reaction against two individual recipient EBV strains appears to be involved...
  48. pmc Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia
    Wolfgang Füreder
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1097 Vienna, Austria
    Am J Pathol 168:123-30. 2006
    ..05). Taken together, these data show that aplastic anemia is associated with reduced angiogenesis and reduced VEGF expression...
  49. ncbi Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Leuk Res 31:727-36. 2007
    ..Respective algorithms and recommendations should facilitate diagnostic and prognostic evaluations in MDS, selection of patients for therapies, and the conduct of clinical trials...
  50. ncbi Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Leuk Res 27:635-41. 2003
    ..This confirms clinical activity in some patients for this drug-combination, but also points to the need to search for more effective strategies in the treatment of patients with aggressive mast cell disorders...
  51. ncbi Mastocytosis: pathology, genetics, and current options for therapy
    Peter Valent
    Department of Internal Medicine I, Medical Univeristy of Vienna, Austria
    Leuk Lymphoma 46:35-48. 2005
    ..Examples include the use of STI571 in patients with SM plus hypereosinophilic syndrome (SM-HES) and the FIPL1/PDGFRA fusion gene target, or chemotherapy for eradication of AML in patients with SM-AML...
  52. ncbi The European Competence Network on Mastocytosis (ECNM)
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
    Wien Klin Wochenschr 116:647-51. 2004
    ..In addition, the ECNM is dedicated to provide the best available information about the disease to patients and physicians...